MACROGENICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions
MACROGENICS, INC. (MGNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions of 5.00% for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions · last filed 2014-11-12
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, discount for postvesting restrictions for the quarter ending 2014-03-31 was 5.00%, a 0.00% change year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, discount for postvesting restrictions for the quarter ending 2013-03-31 was 5.00%.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, discount for postvesting restrictions for fiscal 2012 was 5.57%, a 0.18% decline from fiscal 2011.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, discount for postvesting restrictions for fiscal 2011 was 5.58%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions 12 month |
|---|---|---|---|---|
| 2014-09-30 | 5.00% 10-Q · filed 2014-11-12 | |||
| 2014-06-30 | 5.00% 10-Q · filed 2014-08-05 | |||
| 2014-03-31 | 5.00% 10-Q · filed 2014-05-06 | |||
| 2013-09-30 | 5.06% 10-Q · filed 2014-11-12 | |||
| 2013-06-30 | 5.00% 10-Q · filed 2014-08-05 | |||
| 2013-03-31 | 5.00% 10-Q · filed 2014-05-06 | |||
| 2012-12-31 | 5.57% 10-K · filed 2014-03-20 | |||
| 2012-09-30 | 5.57% 10-Q · filed 2013-11-12 | |||
| 2011-12-31 | 5.58% 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |